Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma
Abroad (travel likely)RecruitingPHASE2
Conditions
Renal Cell Carcinoma · Metastatic Renal Cell Carcinoma · Oligoprogressive · Progression
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Yale University, New Haven, Connecticut, United States
Study leads
Kimberly Johung, MD
Principal Investigator
Yale University